Psoriatic Arthritis Therapeutics Market Size, Share, Industry Trends and Forecast to 2033
This report provides a comprehensive analysis of the Psoriatic Arthritis Therapeutics market, showcasing market size, trends, and forecasts from 2023 to 2033, along with a detailed segmentation, regional insights, and key players in the industry.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $12.00 Billion |
| CAGR (2023-2033) | 8.5% |
| 2033 Market Size | $27.85 Billion |
| Top Companies | AbbVie, Johnson & Johnson, Amgen, Novartis |
| Last Modified Date | 15 Nov 2024 |
Psoriatic Arthritis Therapeutics Market Report (2023 - 2033)
Psoriatic Arthritis Therapeutics Market Overview
What is the Market Size & CAGR of the Psoriatic Arthritis Therapeutics market in 2023?
Psoriatic Arthritis Therapeutics Industry Analysis
Psoriatic Arthritis Therapeutics Market Segmentation and Scope
Request a custom research report for industry.
Psoriatic Arthritis Therapeutics Market Analysis Report by Region
Europe Psoriatic Arthritis Therapeutics Market Report:
The European market for Psoriatic Arthritis therapeutics is poised for significant growth, from $3.19 billion in 2023 to $7.41 billion in 2033. The market is supported by a well-established reimbursement framework and ongoing R&D efforts by pharmaceutical companies.Asia Pacific Psoriatic Arthritis Therapeutics Market Report:
The Asia Pacific market for PsA therapeutics is valued at approximately $2.35 billion in 2023 and is expected to reach $5.45 billion by 2033. Significant growth is driven by increasing patient awareness and access to healthcare services, along with rising healthcare expenditure in emerging economies.North America Psoriatic Arthritis Therapeutics Market Report:
In North America, the PsA therapeutics market is expected to reach $10.78 billion by 2033, growing from $4.65 billion in 2023. The primary drivers include a high prevalence of psoriatic arthritis, extensive research activities, and favorable reimbursement policies.South America Psoriatic Arthritis Therapeutics Market Report:
The South American market is projected to grow from $1.17 billion in 2023 to $2.72 billion by 2033. Factors such as improvements in healthcare infrastructure and increased availability of novel therapies are expected to fuel market growth.Middle East & Africa Psoriatic Arthritis Therapeutics Market Report:
The Middle East and Africa market is projected to increase from $0.64 billion in 2023 to $1.48 billion by 2033, led by rising healthcare investments and increasing awareness programs regarding psoriatic arthritis treatments.Request a custom research report for industry.
Psoriatic Arthritis Therapeutics Market Analysis By Drug Class
Global Psoriatic Arthritis Therapeutics Market, By Drug Class Market Analysis (2023 - 2033)
In 2023, the market for Disease-Modifying Antirheumatic Drugs (DMARDs) is valued at $7.48 billion, holding a 62.35% share. This segment is projected to reach $17.37 billion by 2033, reflecting the efficacy of DMARDs in providing long-term relief and managing disease progression. Non-steroidal Anti-Inflammatory Drugs (NSAIDs) will reach $8.02 billion by 2033 from $3.45 billion in 2023, maintaining a steady share of 28.78%. Corticosteroids, while smaller with $1.06 billion in 2023, are expected to rise to $2.47 billion, representing 8.87% by 2033.
Psoriatic Arthritis Therapeutics Market Analysis By Route Of Administration
Global Psoriatic Arthritis Therapeutics Market, By Route of Administration Market Analysis (2023 - 2033)
The oral route dominates with $7.48 billion in 2023 and a share of 62.35%, while injections and topical formulations contribute $3.45 billion and $1.06 billion, respectively. By 2033, oral administration will maintain its leading position, projected at $17.37 billion, while injections and topical revenues are anticipated at $8.02 billion and $2.47 billion.
Psoriatic Arthritis Therapeutics Market Analysis By Patient Type
Global Psoriatic Arthritis Therapeutics Market, By Patient Type Market Analysis (2023 - 2033)
For adult patients, the market is currently valued at $10.09 billion and is projected to reach $23.43 billion by 2033, capturing an overwhelming 84.12% of the market. Pediatric patients, currently at $1.91 billion, are expected to grow to $4.42 billion, making up 15.88% of the market share.
Psoriatic Arthritis Therapeutics Market Analysis By Indication
Global Psoriatic Arthritis Therapeutics Market, By Indication Market Analysis (2023 - 2033)
The market for mild psoriatic arthritis currently accounts for $7.48 billion and is expected to grow exponentially to $17.37 billion by 2033, sharing 62.35%. Moderate and severe cases are projected to reach $8.02 billion and $2.47 billion, respectively, indicating the need for targeted therapies as disease severity increases.
Psoriatic Arthritis Therapeutics Market Analysis By Distribution Channel
Global Psoriatic Arthritis Therapeutics Market, By Distribution Channel Market Analysis (2023 - 2033)
Retail pharmacies, holding a size of $7.48 billion (62.35% share) in 2023, are expected to grow to $17.37 billion by 2033. Hospital pharmacies and online pharmacies will also capture significant market segments at $8.02 billion and $2.47 billion respectively, by that year.
Psoriatic Arthritis Therapeutics Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Psoriatic Arthritis Therapeutics Industry
AbbVie:
AbbVie is a global biopharmaceutical company leading in research and development of innovative treatments for psoriatic arthritis, particularly with drugs like Humira and Rinvoq.Johnson & Johnson:
Johnson & Johnson focuses on developing comprehensive therapeutics for autoimmune diseases, with drugs like Tremfya addressing psoriatic arthritis.Amgen:
Amgen is known for its advanced biologics including Enbrel, a key treatment for psoriatic arthritis, enhancing patient outcomes.Novartis:
Novartis provides a range of innovative medications targeting various aspects of psoriatic arthritis, including Cosentyx, which has significantly improved therapy options.We're grateful to work with incredible clients.
